BRIEF — Shanghai Shen Lian Says Phase II Clinical Trial Of UB — 221 Meets Primary Endpoint
Sept 20 (Reuters) — Shanghai Shen Lian Biomedical Corp: Says Phase Ii Clinical Trial Of Ub-221 For Chronic Spontaneous Urticaria Treatment Meets Primary Endpoint Source text Further company coverage: (Reporting by Hong Kong newsroom) ((donny.kwok@thomsonreuters.com; +852 3462 7745;)
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.